Silver Book Fact

AFib, an economic burden

Fact image

AFib is a major economic burden for the U.S. with at least $6.65 billion in healthcare costs attributable to the disease each year. This estimate may be low. One study estimates that Medicare alone pays $15.7 billion per year to treat newly diagnosed AFib patients.

Direct Treatment Cost of Atrial Fibrillation in the Elderly American Population: A Medicare perspective. J Med Econ. 2008; 11(2). http://www.ncbi.nlm.nih.gov/pubmed/19450086

Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States. Value in Health. 2006; 9(5). http://www.ncbi.nlm.nih.gov/pubmed/16961553

Reference

Title
Direct Treatment Cost of Atrial Fibrillation in the Elderly American Population: A Medicare perspective
Publication
J Med Econ
Publication Date
2008
Volume & Issue
Volume 11, Issue 2
Pages
281-98
URL
Read Full Resource
Title
Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States
Publication
Value in Health
Publication Date
2006
Volume & Issue
Volume 9, Issue 5
Pages
348-56
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Atrial Fibrillation is Increasingly Prevalent in the United States
    Atrial Fibrillation is Increasingly Prevalent in the United States  
  • Heart failure rates among AFib patients
    A study of Medicare beneficiaries found that those with atrial fibrillation (AF) were significantly more likely to experience heart failure than their non-AF counterparts (36.7% versus 10.4%).  
  • Annual direct cost of Afib
    Average annual cost comparison between patients with and without atrial fibrillation  
  • Atrial fibrillation as the primary discharge diagnosis rates
    Atrial fibrillation was listed as the primary discharge diagnosis in 20.6 per 100,000 people per year for patients between the ages of 15 and 44 and 1,077.4 per 100,000 people…  
  • Atrial fibrillation increases stroke risk
    Atrial fibrillation increases the risk of stroke 5- fold.